135 related articles for article (PubMed ID: 2906500)
1. Chronic uridine treatment reduces the level of [3H]spiperone-labelled dopamine receptors and enhances their turnover rate in striatum of young rats: relationship to dopamine-dependent behaviours.
Farabegoli C; Merlo Pich E; Cimino M; Agnati LF; Fuxe K
Acta Physiol Scand; 1988 Feb; 132(2):209-16. PubMed ID: 2906500
[TBL] [Abstract][Full Text] [Related]
2. Dopamine receptor reappearance after irreversible receptor blockade: effect of chronic estradiol treatment of ovariectomized rats.
Lévesque D; Di Paolo T
Mol Pharmacol; 1991 May; 39(5):659-65. PubMed ID: 1674586
[TBL] [Abstract][Full Text] [Related]
3. Behavioral and radioligand binding evidence for irreversible dopamine receptor blockade by N-ethoxycarbonyl-2-ethoxy-1,2-dihydroquinoline.
Hamblin MW; Creese I
Life Sci; 1983 May; 32(19):2247-55. PubMed ID: 6133202
[TBL] [Abstract][Full Text] [Related]
4. Effect of chronic estradiol treatment on brain dopamine receptor reappearance after irreversible blockade: an autoradiographic study.
Morissette M; Lévesque D; Di Paolo T
Mol Pharmacol; 1992 Sep; 42(3):480-8. PubMed ID: 1357544
[TBL] [Abstract][Full Text] [Related]
5. Effect of aging on recovery of striatal dopamine receptors following N-ethoxycarbonyl-2-ethoxy-1, 2-dihydroquinoline (EEDQ) blockade.
Henry JM; Roth GS
Life Sci; 1984 Aug; 35(8):899-904. PubMed ID: 6482680
[TBL] [Abstract][Full Text] [Related]
6. Inactivation of D1 and D2 dopamine receptors by N-ethoxycarbonyl-2-ethoxy-1,2-dihydroquinoline in vivo: selective protection by neuroleptics.
Meller E; Bohmaker K; Goldstein M; Friedhoff AJ
J Pharmacol Exp Ther; 1985 Jun; 233(3):656-62. PubMed ID: 2861276
[TBL] [Abstract][Full Text] [Related]
7. Analysis of [3H]spiperone binding sites in the rat striatum and frontoparietal cortex by means of quantitative receptor autoradiography after inactivation of dopamine receptors by N-ethoxycarbonyl-2-ethoxy-1,2-dihydroquinoline in vivo: selective protection by sulpiride in the striatum.
Fuxe K; Meller E; Goldstein M; Benfenati F; Agnati LF
Neurosci Lett; 1986 Feb; 64(2):163-8. PubMed ID: 3960398
[TBL] [Abstract][Full Text] [Related]
8. N-(p-isothiocyanatophenethyl)spiperone, a selective and irreversible antagonist of D2 dopamine receptors in brain.
Xu SX; Hatada Y; Black LE; Creese I; Sibley DR
J Pharmacol Exp Ther; 1991 May; 257(2):608-15. PubMed ID: 1674530
[TBL] [Abstract][Full Text] [Related]
9. Effect of aging on striatal dopamine receptor subtype recovery following N-ethoxycarbonyl-2-ethoxy-1,2-dihydroquinoline blockade and relation to motor function in Wistar rats.
Henry JM; Joseph JA; Kochman K; Roth GS
Brain Res; 1987 Aug; 418(2):334-42. PubMed ID: 2960421
[TBL] [Abstract][Full Text] [Related]
10. Chronic haloperidol affects striatal D2-dopamine receptor reappearance after irreversible receptor blockade.
Pich EM; Benfenati F; Farabegoli C; Fuxe K; Meller E; Aronsson M; Goldstein M; Agnati LF
Brain Res; 1987 Dec; 435(1-2):147-52. PubMed ID: 2962698
[TBL] [Abstract][Full Text] [Related]
11. Day/night differences in D1 but not D2 DA receptor protection from EEDQ denaturation in rats treated with continuous cocaine.
Burger LY; Martin-Iverson MT
Synapse; 1993 Jan; 13(1):20-9. PubMed ID: 8093985
[TBL] [Abstract][Full Text] [Related]
12. Dopamine receptor turnover rates in rat striatum are age-dependent.
Leff SE; Gariano R; Creese I
Proc Natl Acad Sci U S A; 1984 Jun; 81(12):3910-4. PubMed ID: 6587399
[TBL] [Abstract][Full Text] [Related]
13. Dopamine denervation does not alter in vivo 3H-spiperone binding in rat striatum: implications for external imaging of dopamine receptors in Parkinson's disease.
Bennett JP; Wooten GF
Ann Neurol; 1986 Apr; 19(4):378-83. PubMed ID: 3707090
[TBL] [Abstract][Full Text] [Related]
14. Differential recovery rates of rat D2 dopamine receptors as a function of aging and chronic reserpine treatment following irreversible modification: a key to receptor regulatory mechanisms.
Norman AB; Battaglia G; Creese I
J Neurosci; 1987 May; 7(5):1484-91. PubMed ID: 2952771
[TBL] [Abstract][Full Text] [Related]
15. Estimation of the apparent affinity of the striatal dopamine receptors for the radioligand[3H]spiperone [( 3H]spiroperidol).
Hruska RE
J Neurosci Res; 1984; 12(4):571-81. PubMed ID: 6512888
[TBL] [Abstract][Full Text] [Related]
16. Relationship between receptor occupancy and response at striatal dopamine autoreceptors.
Meller E; Bohmaker K; Namba Y; Friedhoff AJ; Goldstein M
Mol Pharmacol; 1987 Jun; 31(6):592-8. PubMed ID: 2885734
[TBL] [Abstract][Full Text] [Related]
17. EEDQ, a tool for ex vivo measurement of occupancy of D-1 and D-2 dopamine receptors.
Nowak G; Arnt J; Hyttel J
Eur J Pharmacol; 1988 Aug; 153(2-3):309-11. PubMed ID: 3053212
[TBL] [Abstract][Full Text] [Related]
18. Chronic treatment with dopamine receptor antagonists: behavioral and pharmacologic effects on D1 and D2 dopamine receptors.
Hess EJ; Norman AB; Creese I
J Neurosci; 1988 Jul; 8(7):2361-70. PubMed ID: 2907912
[TBL] [Abstract][Full Text] [Related]
19. Comparison of dopamine receptor sites labeled by [3H]-S-sulpiride and [3H]-spiperone in striatum.
Zahniser NR; Dubocovich ML
J Pharmacol Exp Ther; 1983 Dec; 227(3):592-9. PubMed ID: 6655559
[TBL] [Abstract][Full Text] [Related]
20. In vivo partial inactivation of dopamine D1 receptors induces hypersensitivity of cortical dopamine-sensitive adenylate cyclase: permissive role of alpha 1-adrenergic receptors.
Trovero F; Hervé D; Blanc G; Glowinski J; Tassin JP
J Neurochem; 1992 Jul; 59(1):331-7. PubMed ID: 1351927
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
